Navigation Links
Meningitis in Infancy Erodes Academic Success

One in four teenagers who had meningitis during infancy will not pass any GCSE exams, reveals// research published ahead of print in Archives of Disease in Childhood.

The findings are based on the GCSE exam results of 750 sixteen year olds across England and Wales, 461 of whom had had bacterial meningitis during their first year of life.

The children were all taking part in a long term national study of infantile meningitis in England and Wales.

The General Certificate of Secondary Education exam is taken by 16 year olds in England and Wales. Results are graded A to E, and the national yardstick is to pass five subjects at grade C or above.

Almost 8% (36) of those who had bacterial meningitis before their first birthday were in special schools, which is around four times the national average. All those in the comparison group attended mainstream schools.

One in four who had had the infection did not manage any GCSE passes at grade C or above compared with just over 6% of the comparison group.

Almost half of the teens at state schools who had had meningitis in early childhood failed to achieve the national educational standard of five grade C GSCE passes.

This rate was twice as high as that of children at the same type of school but who had not had meningitis.

More than a fifth failed to pass even one GCSE at grade C compared with 8% of their comparison group and the national average in England of less than 4%.

Even pupils who showed no signs of meningitis associated disability, when assessed at the age of 5, were half as likely to achieve the national standard as children in the comparison group at the same type of school.

All children who have had meningitis in infancy should be closely monitored and provided with continuing educational support throughout their school days, recommend the authors.

Source-Newswise
'"/>




Page: 1

Related medicine news :

1. Meningitis C vaccine a cost-effective success
2. Cure for Bacterial Meningitis
3. Efficacy Of Meningitis C Vaccine
4. Meningitis is rocking the capital again
5. Uganda Tackles The Meningitis Outbreak
6. Fatal Case of Meningitis Detected In Massachusetts
7. Meningitis Back in Delhi and 21 Dead
8. New Delhi Hit By Meningitis Deaths
9. Cost-effective Meningitis Vaccine To Be Launched In Africa
10. Delhi Witnessed 34 Meningitis Deaths In Three Months
11. Meningitis vaccine in a controversy regarding efficacy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... Hackensack, N.J. (PRWEB) , ... April 26, 2017 ... ... fluency, Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine ... program that recognizes the world’s top women business owners. Winners have demonstrated that ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
(Date:4/25/2017)... ... 2017 , ... The doctors at Wall Centre Dental are now expanding their ... require sedation to receive dental care. The doctors offer three treatment options to put ... to oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: